Matcheri S Keshavan Selected Research

Psychotic Disorders (Schizoaffective Disorder)

1/2022	Real-time facial emotion recognition deficits across the psychosis spectrum: A B-SNIP Study.
1/2022	Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.
1/2022	Regional and Sex-Specific Alterations in the Visual Cortex of Individuals With Psychosis Spectrum Disorders.
1/2022	Neurocognitive and social cognitive training for youth at clinical high risk (CHR) for psychosis: A randomized controlled feasibility trial.
1/2022	Psychosis Biotypes: Replication and Validation from the B-SNIP Consortium.
1/2022	Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial.
12/2021	Reduced white matter microstructure in bipolar disorder with and without psychosis.
2/2021	Individualized risk components guiding antipsychotic delivery in patients with a clinical high risk of psychosis: application of a risk calculator.
1/2021	Motivational Interviewing for Loved Ones in Early Psychosis: Development and Pilot Feasibility Trial of a Brief Psychoeducational Intervention for Caregivers.
1/2021	Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matcheri S Keshavan Research Topics

Disease

130	Schizophrenia (Dementia Praecox) 07/2022 - 10/2002
85	Psychotic Disorders (Schizoaffective Disorder) 01/2022 - 01/2002
18	Bipolar Disorder (Manic Depressive Psychosis) 07/2022 - 08/2002
13	Cognitive Dysfunction 11/2022 - 07/2010
6	Mental Disorders (Mental Disorder) 01/2018 - 01/2005
5	Substance-Related Disorders (Drug Abuse) 03/2019 - 07/2004
5	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 05/2014 - 01/2003
3	Mood Disorders (Mood Disorder) 05/2014 - 09/2007
2	Major Depressive Disorder (Major Depressive Disorders) 07/2022 - 11/2003
2	Genetic Risk Score 07/2022 - 01/2021
2	Autistic Disorder (Autism) 04/2016 - 07/2008
2	Disease Progression 03/2015 - 01/2013
2	DiGeorge Syndrome (Syndrome, DiGeorge) 02/2013 - 10/2012
2	Disease Susceptibility (Diathesis) 02/2011 - 03/2006
1	Inflammation (Inflammations) 07/2022
1	Coronary Artery Disease (Coronary Atherosclerosis) 07/2022
1	Wounds and Injuries (Trauma) 01/2022
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2022
1	Cerebral Cortical Thinning 01/2020
1	Hallucinations (Hallucination) 01/2020
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020
1	Hyperglycemia 01/2020
1	Conversion Disorder (Astasia Abasia) 01/2018
1	Encephalitis (Encephalitis, Rasmussen) 02/2013

Drug/Important Bio-Agent (IBA)

63	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 07/2003
34	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2005
18	Biological ProductsIBA 07/2022 - 07/2007
9	Pharmaceutical PreparationsIBA 03/2021 - 05/2005
6	Risperidone (Risperdal Consta)FDA LinkGeneric 01/2015 - 02/2006
6	Phospholipids (Phosphatides)FDA LinkGeneric 01/2013 - 10/2002
5	Protons (Proton)IBA 04/2016 - 07/2008
5	N-acetylaspartate (N-acetyl aspartate)IBA 08/2013 - 07/2007
5	LithiumIBA 03/2009 - 08/2002
4	N,N'-bis(1-decylnipecotoyl)piperazine (BDNP)IBA 12/2021 - 11/2013
4	Cholinergic Antagonists (Anticholinergics)IBA 01/2021 - 11/2012
4	Indicators and Reagents (Reagents)IBA 09/2014 - 01/2003
4	Prednisolone (Predate)FDA LinkGeneric 01/2014 - 03/2008
4	N 30IBA 03/2010 - 01/2003
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2015
3	Glutamic Acid (Glutamate)FDA Link 01/2020 - 08/2013
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2020 - 02/2013
3	Polytetrafluoroethylene (Teflon)FDA Link 03/2019 - 01/2016
3	Complement System Proteins (Complement)IBA 01/2019 - 05/2015
3	purineIBA 01/2013 - 03/2010
3	Phosphorus (Red Phosphorus)IBA 12/2008 - 12/2003
2	C-Reactive ProteinIBA 01/2022 - 01/2015
2	Hormones (Hormone)IBA 12/2018 - 05/2015
2	Oxytocin (Pitocin)FDA LinkGeneric 12/2018 - 11/2014
2	Vasopressins (Vasopressin)IBA 12/2018 - 11/2014
2	Dopamine (Intropin)FDA LinkGeneric 06/2014 - 07/2007
2	N-Methylaspartate (NMDA)IBA 05/2014 - 02/2013
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2013 - 02/2010
2	AntioxidantsIBA 01/2012 - 10/2011
2	Neuroprotective AgentsIBA 07/2010 - 09/2009
2	Phosphates (Orthophosphate)IBA 03/2010 - 07/2006
2	Essential Fatty AcidsIBA 09/2009 - 12/2003
2	CreatineIBA 07/2008 - 11/2005
2	Choline (Choline Chloride)IBA 07/2008 - 11/2005
2	Phosphocreatine (Neoton)IBA 07/2008 - 11/2005
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2005 - 01/2004
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2004 - 10/2002
1	Triglycerides (Triacylglycerol)IBA 07/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 07/2022
1	HDL LipoproteinsIBA 07/2022
1	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 01/2022
1	Hallucinogens (Psychedelics)IBA 01/2022
1	Psilocybin (Psilocibin)IBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 12/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Clozapine (Clozaril)FDA LinkGeneric 01/2021
1	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 01/2020
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2020
1	CytokinesIBA 01/2018
1	Glutathione (Reduced Glutathione)IBA 01/2018
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2017
1	Oxytocin Receptors (Oxytocin Receptor)IBA 03/2016
1	Vitamin D FDA LinkGeneric 08/2015
1	PlasticsIBA 05/2015
1	Histamine (Histamine Dihydrochloride)FDA Link 05/2015
1	GSK239512IBA 05/2015
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 03/2015
1	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2015
1	3'-(1-butylphosphoryl)adenosineIBA 08/2013
1	Valacyclovir (Valtrex)FDA LinkGeneric 07/2013

Therapy/Procedure

24	Therapeutics 05/2022 - 01/2007
10	Cognitive Training 01/2022 - 11/2009
6	Aftercare (After-Treatment) 03/2010 - 01/2002
3	Behavior Control 01/2020 - 09/2014
2	Treatment Delay 01/2021 - 04/2011
2	Transcranial Magnetic Stimulation 01/2019 - 01/2019
2	Drug Therapy (Chemotherapy) 11/2018 - 01/2015
2	Electrodes (Electrode) 01/2012 - 03/2010
1	Institutionalization (Institutionalized Persons) 11/2022
1	Transcranial Direct Current Stimulation 01/2019
1	Precision Medicine 01/2016
1	Ambulatory Care (Outpatient Care) 01/2016
1	Prenatal Care (Care, Prenatal) 07/2015
1	Surgical Instruments (Clip) 01/2015